JUPW - Jupiter Wellnes announces peer-reviewed publication of atopic dermatitis study results

Jupiter Wellness (JUPW) is trading marginally higher after the company announced the publication of clinical study results for JW-100 lotion containing CBD and aspartame for the treatment of atopic dermatitis ((AD)).The changes in AD (eczema) after 14 days of the application of the treatment were assessed using the Investigator's Static Global Assessment ((ISGA)) score.Fifty-seven patients completed the double-blinded placebo-controlled study and JW-100 cohorts have indicated a statistically significant ISGA score reduction (p = 0.042).“The early clinical data shows JW-100's potential to disrupt the billion-dollar market for the treatment of eczema," noted Jupiter Wellness CEO Brian John.The company has started a drug development program for JW-100 targeting AD and initial FDA filings are expected in Q3 2021.The clinical trial results for JW-100 were first announced in February.

For further details see:

Jupiter Wellnes announces peer-reviewed publication of atopic dermatitis study results